ALB and ischemic stroke: However, evidence from both the ALISAH pilot trial [25] and the Albumin in Acute Stroke trial (ALIAS, Parts 1 and 2, ClinicalTrials.gov registration number NCT00235495) [27–29], which evaluated albumin in ischemic stroke patients, suggested that administration of albumin could have deleterious cardiovascular effects due to volume overload [25, 29].